Vitiligo is a condition characterized by a loss of pigment (melanin), which results in the most common symptom: white or ...

New research shows gut-friendly bacteria may slow vitiligo progression, offering hope for millions with autoimmune disease.

Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...

The belief that consuming fish with dairy causes vitiligo is an ancient myth. Science confirms no link, though some may ...

The global dermatology lasers market is set for substantial growth, increasing from USD 1,767.8 billion in 2023 to USD ...

There could be new hope for people afflicted with the skin-discoloring disease, vitiligo. A new treatment reportedly works great on mice with the malady, and it utilizes a natural substance ...

World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting ...

Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

Incyte is preparing to take an oral JAK inhibitor into phase 3 trials for the skin depigmentation disease vitiligo, after reporting mid-stage data showing efficacy in patients with facial and full ...